The Joint Corp (JYNT)vsEli Lilly and Company (LLY)
JYNT
The Joint Corp
$7.75
-4.32%
HEALTHCARE · Cap: $114.56M
LLY
Eli Lilly and Company
$1,185.68
-0.01%
HEALTHCARE · Cap: $1.03T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 135965% more annual revenue ($79.67B vs $58.55M). LLY leads profitability with a 33.5% profit margin vs 6.5%. LLY appears more attractively valued with a PEG of 1.16. LLY earns a higher WallStSmart Score of 76/100 (B+).
JYNT
Hold49
out of 100
Grade: D+
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 653.0% YoY
Every $100 of equity generates 21 in profit
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
Smaller company, higher risk/reward
6.5% margin — thin
Operating margin of 3.3%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : JYNT
The strongest argument for JYNT centers on EPS Growth, Return on Equity, Debt/Equity. Revenue growth of 14.4% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : JYNT
The primary concerns for JYNT are Market Cap, Profit Margin, Operating Margin. A P/E of 57.9x leaves little room for execution misses.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
JYNT profiles as a value stock while LLY is a growth play — different risk/reward profiles.
JYNT carries more volatility with a beta of 1.06 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 49/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
The Joint Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
The Joint Corp. The company is headquartered in Scottsdale, Arizona.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?